Siam Bioscience
Siam Bioscience is a Thai life-sciences company focused on biologics, biosimilars, and related pharmaceutical manufacturing capabilities. It is strategically important because biologics production requires higher technical standards than conventional small-molecule generics, including cell-culture know-how, quality systems, and regulatory validation. The company became especially visible through vaccine and biologics supply-chain discussions, but its broader role is domestic capability-building in advanced medicines. It is not SET-listed and should be treated as a private company with public-health significance.
Profile overview
Siam Bioscience is a Thai life-sciences company focused on biologics, biosimilars, and related pharmaceutical manufacturing capabilities. It is strategically important because biologics production requires higher technical standards than conventional small-molecule generics, including cell-culture know-how, quality systems, and regulatory validation. The company became especially visible through vaccine and biologics supply-chain discussions, but its broader role is domestic capability-building in advanced medicines. It is not SET-listed and should be treated as a private company with public-health significance.
Business segments
Core capability
Biologics manufacturing
Cell-culture-based production of biologic medicines including monoclonal antibodies and recombinant proteins. Requires GMP-grade facilities, validated quality systems, and advanced bioprocess engineering.
Vaccine production
COVID-19 vaccine and biosimilar fill-finish
Siam Bioscience produced AstraZeneca COVID-19 vaccine under a manufacturing agreement during 2021-2022, supplying Thailand and ASEAN markets. Established biologic fill-finish credibility.
Biosimilar pipeline
Biosimilar development and import substitution
Biosimilar medicines can replace expensive imported reference biologics in hospital formularies. Thai FDA approval pathway and NLEM inclusion are the critical go-to-market gates for each product.
Ownership
Crown Property Bureau affiliation
Affiliated with the Crown Property Bureau, which provides strategic patient capital and alignment with public-health objectives rather than short-term commercial returns.
Thai pharmaceutical manufacturer peer comparison
Capability tier and listing status
Ticker
Private (CPB-affiliated)
Manufacturing type
Biologics, biosimilars
Market scope
Domestic, ASEAN supply
GPO (Govt. Pharma Org.)
Ticker
Government SOE
Manufacturing type
Generic drugs, vaccines
Market scope
Public hospital procurement
T.O. Chemicals
Ticker
SET:TOC
Manufacturing type
API, generics
Market scope
Domestic, export
Pharmaland
Ticker
Private
Manufacturing type
Generic formulation
Market scope
Domestic hospitals, retail
MNC subsidiaries
Ticker
Various
Manufacturing type
Branded originals
Market scope
Domestic retail, hospital
| Manufacturer | Ticker | Manufacturing type | Market scope |
|---|---|---|---|
| Siam Bioscience | Private (CPB-affiliated) | Biologics, biosimilars | Domestic, ASEAN supply |
| GPO (Govt. Pharma Org.) | Government SOE | Generic drugs, vaccines | Public hospital procurement |
| T.O. Chemicals | SET:TOC | API, generics | Domestic, export |
| Pharmaland | Private | Generic formulation | Domestic hospitals, retail |
| MNC subsidiaries | Various | Branded originals | Domestic retail, hospital |
Key drivers 2025-2026
Regulatory pathway
Thai FDA biosimilar approvals
ACTD and eCTD filing pathways for biosimilars require comprehensive manufacturing data and clinical bridging studies. FDA review timelines determine when new products enter public procurement.
Procurement access
NLEM and public hospital formulary
National List of Essential Medicines inclusion is the critical gateway for hospital-volume purchasing. Biosimilar uptake depends on physician acceptance and pharmacoeconomic evaluation.
Technology transfer
Regional biologics hub ambition
Thailand's aspiration to become a regional biologics manufacturing hub depends on Siam Bioscience's manufacturing track record, regulatory credibility, and cost competitiveness vs Indian and Chinese makers.
Source-pack context
Siam Bioscience is linked to existing Insight report coverage through tracked source packs. The cited sources provide the current evidence trail for market context, regulatory exposure, operator positioning, or sector structure; exact numeric claims should still be checked against raw snapshots before being surfaced as headline metrics.[, , ]
Deep operating read
Siam Bioscience is positioned as a royal-backed biologics and biosimilar manufacturer inside Thailand's import-heavy pharmaceutical market. The report frames Thai pharma at THB 220-280B annually, with roughly 60% multinational-imported branded pharma and 40% Thai domestic generic production. GPO anchors the domestic public side, while Siam Bioscience represents the higher-technical biologics/biosimilar capability layer. Its strategic value is import substitution and biologics know-how, not simply conventional generic volume.[, , , ]
Execution watchpoints
Siam Bioscience's outlook depends on Thai FDA pathway evolution, biosimilar acceptance, and public procurement substitution. The Drug Act, ACTD/eCTD pathway, and NLEM framework create the regulatory rails for new products and generic-equivalent substitution. The 2007-2008 compulsory-licensing precedent remains a policy signal for essential-medicine pricing leverage, but biologics require stronger manufacturing validation. Underwrite product pipeline, Thai FDA approvals, and hospital procurement access separately from ownership prestige.[, , , ]
Related Market profiles
Peers, parents, partners, agencies, and other Pharmaceutical Imports, Multinationals, and Generic Pathways actors.
Partner
Government Pharmaceutical Organization (GPO)
Thai state pharmaceutical manufacturer; produces essential medicines, vaccines, and APIs under MoPH mandate for public-health security.
Open Market profile →
Partner
Thailand Food and Drug Administration (Thai FDA)
Thai MoPH agency licensing and regulating food, drugs, cosmetics, medical devices, and controlled substances.
Open Market profile →
Reports featuring this profile
Thailand AI Drug Discovery & Pharma-Biotech 2027 Market Intelligence
Biologics manufacturer, AstraZeneca legacy partner, AI biologic candidate carrier
Open report →
Sits alongside 2 other Atlas profilesThailand Pharmaceutical Manufacturing Market Intelligence
Crown Property Bureau-affiliated biologics and vaccine plant (AstraZeneca tech-transfer)
Open report →
Sits alongside 4 other Atlas profilesThai Pharmaceutical: GPO State Pharma, Generic Production, and the Patent-Pool ARV Heritage
Crown Property Bureau-affiliated biotech; AstraZeneca COVID-vaccine 2021-2022.
Open report →
Sits alongside 5 other Atlas profilesThe Thai Pharma Import Lane: Multinational Brands, Thai-FDA Pathway, and Generic Substitution
Royal-backed biologics, biosimilar manufacturer.
Open report →
Sits alongside 5 other Atlas profilesRelated Market profiles
partner
Government Pharmaceutical Organization (GPO)
Thai state pharmaceutical manufacturer; produces essential medicines, vaccines, and APIs under MoPH mandate for public-health security.
partner
Thailand Food and Drug Administration (Thai FDA)
Thai MoPH agency licensing and regulating food, drugs, cosmetics, medical devices, and controlled substances.